Previous 10 | Next 10 |
2024-01-04 13:17:57 ET More on Scholar Rock Scholar Rock Holding Corporation (SRRK) Q3 2023 Earnings Call Transcript Scholar Rock Holding Corporation 2023 Q3 - Results - Earnings Call Presentation Scholar Rock: SMA Data Readout In 2024 Makes This Worth A Look ...
- Advancing industry-leading antimyostatin pipeline, comprised of multiple, novel assets with unparalleled selectivity, to treat spinal muscular atrophy (SMA) and cardiometabolic disorders - Completed enrollment for apitegromab pivotal Phase 3 SAPPHIRE trial in patients with SMA; toplin...
2024-01-02 13:57:42 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Americans live longer than ever, and a handful of biotech stocks stand at the forefront of longevity’s future. Many misconceive anti-aging stocks as peddling some magic pill that ine...
2023-12-29 10:00:03 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Healthcare and utilities could perform better in 2024 - analyst Arcus, Bristol-Myers, ...
2023-12-27 10:25:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 42 nd Annual Healthcare Conference on Tuesday, ...
2023-12-14 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Ocular Therape...
2023-11-07 14:18:02 ET Scholar Rock Holding Corporation (SRRK) Q3 2023 Earnings Conference Call November 07, 2023 08:00 AM ET Company Participants Rushmie Nofsinger - Vice President, Investor Relations & Corporate Affairs Jay Backstrom - Chief Executive Officer ...
2023-11-07 07:32:18 ET More on Scholar Rock Scholar Rock: SMA Data Readout In 2024 Makes This Worth A Look Scholar Rock: The Market Isn't Enthusiastic Despite Decent Clinical Data Jefferies upgrades Scholar Rock to buy; cites SMA, obesity drug assets Scholar ...
Completed enrollment for pivotal Phase 3 SAPPHIRE trial evaluating apitegromab; topline data expected in 4Q 2024 Expanding into cardiometabolic disorders with SRK-439, a novel investigational myostatin inhibitor Presented new data supporting proof of concept for SRK-181 in heavily...
News, Short Squeeze, Breakout and More Instantly...
Scholar Rock Holding Corporation Company Name:
SRRK Stock Symbol:
NASDAQ Market:
2024-06-13 08:00:15 ET Etzer Darout from BMO Capital issued a price target of $31.00 for SRRK on 2024-06-13 07:24:00. The adjusted price target was set to $31.00. At the time of the announcement, SRRK was trading at $9.39. The overall price target consensus is at $28.50 ...
Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patients Analysis of baseline biomarker data in clear cell renal cell carcinoma (ccRCC) patients reveals a doubling of the ORR highlighting a potential patient selection strategy ...
- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3 rd , at 1:50 p.m CDT/2:50 p.m. EDT - Company will host conference call to discuss the data on Tuesday, June 4 th at 7:00 a.m. CDT/8:00 a.m. EDT Scholar Rock (NASDA...